SCHEMBL3169447

SCHEMBL3169447

O=c1c2ncccc2nc(C2CCC(C(F)(F)F)CC2)n1-c1ccc(F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 4/20 0.40
PDE4B Q07343 3/20 0.40
PDE4D Q08499 2/20 0.40
HRH3 Q9Y5N1 1/20 0.40
AOC3 Q16853 1/20 0.36
HCAR1 Q9BXC0 1/20 0.35
HTR1A P08908 1/20 0.35
DRD2 P14416 1/20 0.35
HTR2A P28223 1/20 0.35
HTR7 P34969 1/20 0.35
HTR6 P50406 1/20 0.35
ALDH1A1 P00352 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MCHR1 Q99705 1/20 0.33
EP300 Q09472 1/20 0.33
CREBBP Q92793 1/20 0.33
KAT2A Q92830 1/20 0.33
KAT2B Q92831 1/20 0.33
PDE4A P27815 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3169440 1.00 SCN9A (0.40) SCN9APDE4BPDE4DHRH3AOC3
SCHEMBL3185944 0.91 PDE4B (0.39) PDE4BPDE4DHRH3HCAR1HTR1A
SCHEMBL3185951 0.91 PDE4B (0.39) PDE4BPDE4DHRH3HCAR1HTR1A
SCHEMBL3177168 0.88 PDE4B (0.42) PDE4BPDE4DHRH3PDE4A
SCHEMBL3177174 0.88 PDE4B (0.42) PDE4BPDE4DHRH3PDE4A
SCHEMBL3174423 0.86 PDE4B (0.36) PDE4BPDE4DHRH3HCAR1SMN1; SMN2
SCHEMBL3174425 0.86 PDE4B (0.36) PDE4BPDE4DHRH3HCAR1SMN1; SMN2
SCHEMBL3169708 0.83 PDE4B (0.44) PDE4BPDE4DHRH3PDE4A
SCHEMBL3169713 0.83 PDE4B (0.44) PDE4BPDE4DHRH3PDE4A
SCHEMBL3175431 0.83 PDE4B (0.45) PDE4BPDE4DHRH3HCAR1MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100008866-A1 CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2010-01-14 US claimed
EP-2094704-A2 CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES Neurogen Corporation (US) 2009-09-02 EP claimed
WO-2008066664-A2 CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2008-06-05 WO claimed
US-20100008866-A1 CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2010-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100008866-A1 CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES PIGS, GPR174, GPR17 SCN9A 2773/4885PDE4B 1345/4885PDE4D 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.